Bayer

This study tests whether adding finerenone to standard blood pressure medicines can reduce protein in the urine of children with chronic kidney disease. About 219 children aged 6 months to under 18 years will take either finerenone or a placebo for 6 months. The goal is to see if…

This study follows 100 adults and children with advanced or recurrent TRK fusion cancer who are taking larotrectinib as part of their routine care. Researchers will collect information from medical records and interviews to learn about the drug's safety and how well it controls t…

This early-phase study tests a new drug, BAY 3498264, combined with the approved targeted therapy sotorasib in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to find a safe dose and see if the combination can delay or overcome resistance. A…

This study tests a new drug, 225Ac-PSMA-Trillium, in people with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug delivers radiation directly to cancer cells to damage them. The main goals are to check safety, find the best dose, and se…

This study tests an experimental drug called BAY 3401016 in 60 adults aged 18 to 45 with Alport syndrome, a rare genetic condition that leads to kidney failure. The drug blocks a protein thought to cause kidney damage, aiming to reduce protein in the urine and slow the loss of ki…

This study tests a medicine called finerenone in children aged 6 months to 18 years who have heart failure with a weak left heart pump. The medicine aims to reduce heart stress and improve function. About 111 children will receive either finerenone or a placebo for 3 months, alon…

This early-stage study tests a new medicine called BAY 3389934 in up to 36 adults with sepsis who have blood clotting issues. The goal is to find a safe dose and see how the drug affects the body. Participants are in the ICU and will be monitored for about 28 days.

This study looks at the long-term safety of adding finerenone to standard blood pressure medicines for children aged 1 to 18 with chronic kidney disease and protein in their urine. About 100 participants who were in a previous finerenone study will take the drug for up to 18 mont…

This study is for men with high-risk prostate cancer that hasn't spread. Before surgery to remove the prostate, participants will receive a drug combination (darolutamide plus hormone therapy) for either 12 weeks or 24 weeks. The goal is to see which treatment duration leads to b…

This observational study follows 600 Korean men with prostate cancer who are already prescribed darolutamide. The goal is to track side effects and see how well the drug works over one year. Researchers will review medical records during routine doctor visits every 2 to 4 months.

This phase 3 study tests a new daily pill, sevabertinib, against standard intravenous chemotherapy for people with advanced non-small cell lung cancer that has specific HER2 mutations. About 444 adults will be randomly assigned to receive either the pill or standard treatment. Th…

This study tests whether the Mirena IUD can reverse noncancerous thickening of the uterine lining better than daily oral hormone pills. About 207 women will receive either Mirena or oral medroxyprogesterone for 6 months. The goal is to see if the lining returns to normal and stay…

This study follows 480 people with neovascular glaucoma who are already receiving Eylea treatment. Researchers will track side effects and measure eye pressure, vision changes, and blood vessel growth over 6 months. The goal is to see how safe and effective Eylea is in routine me…

This study observes 500 adults in South Korea with chronic kidney disease and type 2 diabetes who are starting finerenone as part of their routine care. Researchers will collect data on patient characteristics, treatment patterns, and side effects over up to 12 months. The goal i…

This early-stage study tests a new drug, BAY 3771249, for people with advanced colorectal cancer that has a specific KRAS G12D mutation. The drug aims to block the faulty protein and slow cancer growth. About 130 adults will receive the drug alone or with cetuximab to find safe d…

This early-stage study tests a new drug, BAY 3547926, that delivers a small amount of radiation directly to liver cancer cells. It is for people with advanced hepatocellular carcinoma (HCC) that has a specific protein called GPC3. The goal is to find a safe dose and see if the dr…

This study looks at whether switching from tafamidis to acoramidis can increase blood levels of a key protein (TTR) in adults with a heart condition called ATTR-CM. The condition happens when a protein breaks down and clogs the heart. About 50 people who have been on tafamidis fo…

This program provides oral sevabertinib to adults with advanced non-small cell lung cancer that has a specific HER2 gene mutation and has stopped responding to other treatments. Participants must have a life expectancy of at least 12 weeks and be well enough to perform daily acti…

This study tests an oral drug called BAY 2927088 (sevabertinib) in adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and slow or shrink the cancer. About 111 participants will take the drug daily until their cancer w…

This study tests a new drug called BAY 3713372 in people with solid tumors that lack a gene called MTAP. The drug works by blocking a protein that helps these cancer cells grow, while leaving normal cells alone. The main goals are to check the drug's safety, how the body processe…

This study is for Indian men with a type of prostate cancer that has not spread but keeps growing even when testosterone levels are very low. Participants will take darolutamide pills twice a day along with standard hormone therapy. The main goal is to check how safe the drug is …

This study looks at whether hydrotalcite (Talcid) can relieve acid-related symptoms like heartburn that occur after stopping long-term use of proton pump inhibitors (PPIs). About 167 adults in Germany who have stopped taking PPIs and are experiencing rebound symptoms will take hy…

This study looks at why some people develop kidney problems after heart surgery. Researchers will collect blood and urine samples from 200 adults before and after their scheduled heart surgery to measure certain biological markers. Participants receive no experimental treatment—o…

This study monitors the safety and effectiveness of Verquvo in 1,350 Korean adults with chronic heart failure with reduced ejection fraction. Participants take Verquvo as prescribed by their doctor, and researchers collect data on side effects, hospital stays, and deaths over up …

This study observes 300 people with Parkinson's disease who still have movement problems despite taking standard medications. Researchers will collect data on symptoms, treatments, and daily challenges over up to 5 years. The goal is to better understand how the disease changes o…

This study will analyze health data from up to 50,000 people in Germany to find out how common three eye diseases—nAMD, DME, and RVO—are and how they have changed from 2009 to 2024. Researchers will look at two large sets of health records to see how many new cases occur each yea…

This study looks at the safety of finerenone, a drug already approved for chronic heart failure, in 300 adults in South Korea. Participants take the drug as prescribed by their doctor, and researchers collect data from routine care for one year. The goal is to see how safe and ef…

This study follows about 20 Korean people aged 12 and older with hemophilia A who are already taking Jivi as prescribed by their doctor. Researchers will collect information from routine clinic visits to see how safe the drug is in real-world use. No extra tests or visits are req…

This study looks at medical records of 100 Japanese men with low-volume metastatic hormone-sensitive prostate cancer who are taking darolutamide plus standard hormone therapy and chemotherapy. Researchers want to see how safe the combination is and how well it controls the cancer…

This study looks at 50,000 people in Asia and the US who have chronic kidney disease and type 2 diabetes and are already taking finerenone as part of their regular care. Researchers will collect information from medical records to see how the drug is being used, who is taking it,…

This study observes how men with metastatic hormone-sensitive prostate cancer (mHSPC) are treated with darolutamide in everyday urology clinics across the US. Researchers will review medical records of about 1,400 patients to understand who gets which treatment (darolutamide with…

This study looks at how often a medicine called Eylea is used in preterm babies with retinopathy of prematurity (ROP), an eye disease that can cause blindness. Researchers will collect data from a UK database on up to 200 babies treated with Eylea using a special pediatric dosing…

This study looks at prescription records from Australian databases to understand how men with advanced prostate cancer are treated in everyday practice. Researchers will analyze data from 1,000 adult men to see which drugs are used, how long they are taken, and patient characteri…

This study is observing adults and children with advanced TRK fusion cancer who are already being treated with the drug VITRAKVI (larotrectinib). Researchers will collect information from routine doctor visits to see how well the drug controls the cancer and what side effects occ…

This study is observing up to 2,000 adults across Europe who are starting a new medication called acoramidis for a serious heart condition (ATTR-CM). The goal is to see how the drug works in everyday medical practice, not in a strict trial setting. Researchers will track patient …

This study looks at how women treated their menopause hot flashes before and after taking part in earlier clinical trials (OASIS 1, 2, or 3). Researchers will survey participants and review anonymous medical records to see which treatments they used, whether they stuck with them,…

This study looks at how well a test measures the kidneys' extra filtering ability, called renal functional reserve. Up to 50 adults, both healthy and with stable kidney problems, will drink a protein shake and provide blood and urine samples over three visits. The goal is to see …

This study looks at the safety of a drug called vericiguat in Japanese people with chronic heart failure. Researchers will track side effects and see how long the drug can prevent heart-related deaths compared to standard care. About 1400 participants will be followed for up to 2…

This early-stage study tests a new drug, BAY 3389934, in 16 healthy Japanese adults to see if it is safe and how the body handles it. The drug is being developed for a serious blood clotting problem that can happen with severe infections. Participants receive either the drug or a…